INmune Bio

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell INmune Bio and other ETFs, options, and stocks.

About INMB

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL. 

CEO
David J. Moss
CEODavid J. Moss
Employees
21
Employees21
Headquarters
Boca Raton, Florida
HeadquartersBoca Raton, Florida
Founded
2015
Founded2015
Employees
21
Employees21

INMB Key Statistics

Market cap
57.37M
Market cap57.37M
Price-Earnings ratio
-3.01
Price-Earnings ratio-3.01
Dividend yield
Dividend yield
Average volume
321.49K
Average volume321.49K
High today
$2.11
High today$2.11
Low today
$1.78
Low today$1.78
Open price
$1.97
Open price$1.97
Volume
953.03K
Volume953.03K
52 Week high
$2.61
52 Week high$2.61
52 Week low
$1.09
52 Week low$1.09

Stock Snapshot

The current INmune Bio(INMB) stock price is $2.02, with a market capitalization of 57.37M. The stock trades at a price-to-earnings (P/E) ratio of -3.01.

During the trading session on 2026-08-08, INmune Bio(INMB) shares reached a daily high of $2.11 and a low of $1.78. At a current price of $2.02, the stock is +13.3% higher than the low and still -4.0% under the high.

Trading volume for INmune Bio(INMB) stock has reached 953.03K, versus its average volume of 321.49K.

Over the past 52 weeks, INmune Bio(INMB) stock has traded between a high of $2.61 and a low of $1.09.

Over the past 52 weeks, INmune Bio(INMB) stock has traded between a high of $2.61 and a low of $1.09.

INMB News

Nasdaq 2d
INmune Bio Q2 2026 Earnings Call Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

INmune Bio Q2 2026 Earnings Call Transcript
Investing.com 2d
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com

...

Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com

People also own

Based on the portfolios of people who own INMB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.